IN VIVO

Scope & Guideline

Fostering scientific excellence in biochemistry and cancer studies.

Introduction

Immerse yourself in the scholarly insights of IN VIVO with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0258-851x
PublisherINT INST ANTICANCER RESEARCH
Support Open AccessNo
CountryGreece
TypeJournal
Convergefrom 1987 to 2024
AbbreviationIN VIVO / In Vivo
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE

Aims and Scopes

The journal "IN VIVO" primarily focuses on the translational aspects of biological and medical research, emphasizing in vivo studies that bridge laboratory findings and clinical applications. This journal serves as a platform for sharing innovative research that contributes to understanding disease mechanisms, treatment strategies, and therapeutic interventions.
  1. Translational Medicine:
    Research that connects laboratory findings with clinical applications, aiming to enhance patient care and treatment outcomes.
  2. Oncology and Cancer Research:
    A significant focus on various aspects of cancer research, including novel treatment modalities, prognostic factors, and molecular mechanisms underlying tumorigenesis.
  3. Pharmacology and Drug Development:
    Studies exploring drug efficacy, mechanisms of action, and the impact of pharmacogenomics on treatment responses.
  4. Regenerative Medicine and Tissue Engineering:
    Research involving stem cells, tissue scaffolds, and regenerative therapies to repair or replace damaged tissues.
  5. Immunology and Inflammatory Diseases:
    Investigations into immune responses, inflammation processes, and their implications in various diseases, particularly cancer and autoimmune conditions.
  6. Surgical Techniques and Outcomes:
    Evaluation of surgical interventions, including innovative surgical techniques, their effectiveness, and patient outcomes.
  7. Biomarkers and Diagnostic Tools:
    Research aimed at identifying novel biomarkers for disease diagnosis, prognosis, and monitoring therapeutic responses.
As the journal "IN VIVO" evolves, certain themes are emerging as key areas of focus. This section outlines these trending scopes, indicating the directions in which research is increasingly heading.
  1. Precision Medicine and Personalized Therapies:
    Research focused on tailoring treatments to individual patient characteristics, including genetic profiling and targeted therapies, is gaining momentum.
  2. Immunotherapy and Cancer Vaccines:
    An increase in studies exploring the efficacy and mechanisms of immunotherapy and novel cancer vaccines, reflecting the growing importance of these approaches in oncology.
  3. Regenerative Medicine Innovations:
    Emerging techniques in regenerative medicine, including the application of stem cells and biomaterials for tissue repair, are becoming more prevalent.
  4. Artificial Intelligence in Medical Research:
    The integration of artificial intelligence and machine learning in analyzing research data, predicting outcomes, and improving diagnostic accuracy is on the rise.
  5. Longitudinal Studies on Treatment Outcomes:
    A trend towards conducting long-term studies that assess the outcomes of various treatment modalities in cancer and other chronic diseases.
  6. Microbiome Research:
    Increasing interest in the role of the microbiome in health, disease progression, and treatment efficacy, particularly in cancer therapy.

Declining or Waning

While "IN VIVO" continues to thrive in various research areas, certain themes appear to be declining in prominence. This section identifies these waning scopes, highlighting the potential shift in research focus within the journal.
  1. Basic Science Research:
    There seems to be a decline in purely basic science studies that do not translate into clinical applications, as the journal increasingly prioritizes research with direct clinical relevance.
  2. Animal Models of Non-Oncological Diseases:
    Research focusing on animal models for diseases other than cancer appears less frequent, possibly due to a greater emphasis on cancer-related studies and translational impacts.
  3. Epidemiological Studies:
    Epidemiological research that does not directly tie into clinical interventions or outcomes has seen reduced representation, suggesting a shift towards more intervention-focused studies.
  4. Traditional Diagnostic Methods:
    There is a noticeable decrease in studies focusing on conventional diagnostic methods, as the journal shifts towards innovative techniques and biomarkers.

Similar Journals

Immuno

Advancing Immunology Through Open Access Innovation
Publisher: MDPIISSN: Frequency: 4 issues/year

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

TISSUE & CELL

Unveiling the Mysteries of Cells and Tissues
Publisher: CHURCHILL LIVINGSTONEISSN: 0040-8166Frequency: 6 issues/year

TISSUE & CELL is a prominent academic journal, published by CHURCHILL LIVINGSTONE, that has been at the forefront of research in the fields of cell biology, developmental biology, and miscellaneous areas of medicine since its inception in 1969. With a strong focus on high-quality research, TISSUE & CELL has established itself within the academic community, holding a Q3 ranking in both Cell Biology and Developmental Biology, and a Q2 ranking in Medicine as of 2023. The journal aims to disseminate significant findings that contribute to the understanding of tissue structure and function, helping to bridge the gap between basic biological research and clinical applications. While it operates on a subscription basis and does not currently offer Open Access options, the journal remains a vital resource for researchers, professionals, and students interested in cutting-edge developments in the biological sciences. The journal's address is located in the scenic city of Edinburgh, further establishing its academic heritage in the United Kingdom.

EXPERIMENTAL AND MOLECULAR PATHOLOGY

Advancing the frontiers of disease understanding.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0014-4800Frequency: 6 issues/year

EXPERIMENTAL AND MOLECULAR PATHOLOGY, a distinguished journal published by Academic Press Inc Elsevier Science, is recognized for its significant contributions to the fields of pathology, clinical biochemistry, and molecular biology. With an ISSN of 0014-4800 and an E-ISSN of 1096-0945, this journal provides a platform for the dissemination of high-quality research articles, reviews, and experimental studies that deepen our understanding of disease mechanisms and diagnostic pathways. Since its inception in 1962 and through its converged publication years, the journal has consistently maintained a solid impact in the academic community, achieving high Scopus rankings—ranked #15 in the field of Pathology and Forensic Medicine and #22 in Clinical Biochemistry, showcasing a commendable percentile standing of 93rd and 81st respectively in 2023. The journal is accessible through various academic libraries and institutional subscriptions, making it an essential resource for researchers, professionals, and students committed to advancing knowledge in these critical areas. With a categorization that includes Q1 rankings in Pathology and Forensic Medicine, EXPERIMENTAL AND MOLECULAR PATHOLOGY stands as a prominent venue for pioneering scientific inquiry and collaborative advancement in molecular diagnostics and therapeutic strategies.

MedComm

Fostering Collaboration in Cutting-Edge Medical Research
Publisher: WILEYISSN: Frequency: 4 issues/year

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

JOURNAL OF BIOMEDICAL SCIENCE

Empowering research through open access in biomedicine.
Publisher: BMCISSN: 1021-7770Frequency: 1 issue/year

JOURNAL OF BIOMEDICAL SCIENCE, published by BMC, is a premier Open Access journal dedicated to the rapid dissemination of research in the fields of biomedical science, encompassing crucial areas such as biochemistry, cell biology, clinical biochemistry, and more. Since its inception in 1993, the journal has established itself as a leading publication, currently boasting a remarkable impact factor and quality as evidenced by its Q1 quartile rankings across multiple categories in 2023. With an impressive track record, including a Scopus ranking in the top percentiles across several disciplines, it serves as a vital resource for researchers, professionals, and students who are keen on advancing their knowledge in biomedicine. The journal operates under a fully Open Access model, ensuring that all published articles are freely available to the global research community, thus contributing to the broader dissemination and accessibility of scientific knowledge. Based in the United Kingdom, JOURNAL OF BIOMEDICAL SCIENCE is committed to fostering innovation and collaboration in research, appealing to those aiming to make impactful contributions to the biomedical sphere.

International Journal of Molecular and Cellular Medicine

Fostering Collaboration in Cutting-edge Molecular Research
Publisher: CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTERISSN: 2251-9637Frequency: 4 issues/year

International Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.

EXPERIMENTAL AND MOLECULAR MEDICINE

Empowering researchers with open access to cutting-edge findings.
Publisher: SPRINGERNATUREISSN: 1226-3613Frequency: 12 issues/year

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

Translational Research

Fostering Collaboration for a Healthier Future
Publisher: ELSEVIER SCIENCE INCISSN: 1931-5244Frequency: 12 issues/year

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

Cell Reports Medicine

Bridging molecular discoveries and clinical innovations.
Publisher: CELL PRESSISSN: 2666-3791Frequency: 12 issues/year

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

BioImpacts

Catalyzing innovative research for a healthier future.
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5652Frequency: 4 issues/year

BioImpacts, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, is a prominent platform dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Medicine, and Pharmaceutical Science. Established in 2011, this Open Access journal ensures that vital research findings are freely accessible to the global academic community. With an impressive presence in the Scopus database, BioImpacts currently holds a Q2 quartile ranking in its respective categories, reflecting its contribution to scientific discourse and its importance as a critical resource for researchers and practitioners alike. The journal's dynamic scope encompasses a wide range of topics, highlighting innovative research that addresses contemporary challenges in health and disease. Operating out of Tabriz, Iran, BioImpacts is committed to fostering interdisciplinary collaboration and knowledge dissemination through their dedicated publication efforts, which span from 2011 to 2024. Researchers, professionals, and students are encouraged to explore the rich content and cutting-edge studies presented in this journal, making it an indispensable resource in the scientific community.